Active substance
Phentermine
- US FDA 100
- US price lines 6
- Safety 1
US FDA United States — FDA approvals (Drugs@FDA)
| Product | Strength | Form · route | Applicant | Status | First approved |
|---|---|---|---|---|---|
| ADIPEX-P | 37.5MG | tablet · oral | TEVA | Prescription | 22 Oct 1980 |
| PHENTERMINE HYDROCHLORIDE | 30MG; 15MG | capsule · oral | SANDOZ | Prescription | 12 Jun 1981 |
| PHENTERMINE HYDROCHLORIDE | 30MG | capsule · oral | SANDOZ | Prescription | 20 Jul 1983 |
| PHENTERMINE HYDROCHLORIDE | 37.5MG | tablet · oral | ELITE LABS INC | Prescription | 30 May 1997 |
| PHENTERMINE HYDROCHLORIDE | 37.5MG | tablet · oral | PRINSTON INC | Prescription | 4 Jan 2002 |
| PHENTERMINE HYDROCHLORIDE | 37.5MG | tablet · oral | SUN PHARM INDUSTRIES | Prescription | 23 Oct 2003 |
| PHENTERMINE HYDROCHLORIDE | 30MG | capsule · oral | KVK TECH | Prescription | 21 Mar 2008 |
| PHENTERMINE HYDROCHLORIDE | 37.5MG | tablet · oral | KVK TECH | Prescription | 31 Mar 2008 |
| PHENTERMINE HYDROCHLORIDE | 30MG; 15MG | capsule · oral | KVK TECH | Prescription | 31 Mar 2008 |
| PHENTERMINE HYDROCHLORIDE | 37.5MG | capsule · oral | KVK TECH | Prescription | 24 Apr 2008 |
| PHENTERMINE HYDROCHLORIDE | 37.5MG | tablet · oral | ELITE LABS | Prescription | 31 Jan 2011 |
| PHENTERMINE HYDROCHLORIDE | 15MG; 30MG | capsule · oral | ELITE LABS | Prescription | 28 Sep 2012 |
| PHENTERMINE HYDROCHLORIDE | 37.5MG | tablet · oral | AUROBINDO PHARMA LTD | Prescription | 6 Aug 2014 |
| PHENTERMINE HYDROCHLORIDE | 37.5MG | tablet · oral | NUVO PHARM | Prescription | 25 Sep 2014 |
| PHENTERMINE HYDROCHLORIDE | 37.5MG | capsule · oral | NUVO PHARM | Prescription | 25 Sep 2014 |
| PHENTERMINE HYDROCHLORIDE | 15MG; 30MG | capsule · oral | NUVO PHARM | Prescription | 5 Dec 2014 |
| LOMAIRA | 8MG | tablet · oral | AVANTHI INC | Prescription | 12 Sep 2016 |
| PHENTERMINE HYDROCHLORIDE | 15MG; 30MG | capsule · oral | AUROLIFE PHARMA LLC | Prescription | 9 Nov 2016 |
| PHENTERMINE HYDROCHLORIDE | 37.5MG | tablet · oral | PURACAP LABS BLU | Prescription | 18 Nov 2016 |
| PHENTERMINE HYDROCHLORIDE | 8MG | tablet · oral | KVK TECH INC | Prescription | 17 Mar 2017 |
| PHENTERMINE HYDROCHLORIDE | 15MG; 30MG; 37.5MG | tablet, orally disintegrating · oral | ZYDUS PHARMS | Prescription | 28 Jun 2017 |
| FASTIN | 30MG **Federal Register determination that product was not discontinued or withdrawn for safety or effectiveness reasons** | capsule · oral | GLAXOSMITHKLINE | Discontinued | 14 Aug 1973 |
| TORA | 8MG | tablet · oral | SOLVAY | Discontinued | 24 Feb 1976 |
| PHENTERMINE HYDROCHLORIDE | 8MG | tablet · oral | CHARTWELL RX | Discontinued | 1 Jul 1976 |
| PHENTERMINE HYDROCHLORIDE | 8MG | tablet · oral | CHARTWELL RX | Discontinued | 14 Mar 1977 |
75 more — full table
Prices — United States and England
| Source | Product as listed | Price | Unit / pack | Date |
|---|---|---|---|---|
| US NADAC | LOMAIRA 8 MG TABLET | $0.61814 | per EA | 23 Sep 2026 |
| US NADAC | PHENTERMINE 15 MG CAPSULE | $0.10137 | per EA | 23 Sep 2026 |
| US NADAC | PHENTERMINE 30 MG CAPSULE | $0.12596 | per EA | 23 Sep 2026 |
| US NADAC | PHENTERMINE 37.5 MG CAPSULE | $0.1051 | per EA | 23 Sep 2026 |
| US NADAC | PHENTERMINE 37.5 MG TABLET | $0.07268 | per EA | 23 Sep 2026 |
| US NADAC | PHENTERMINE 8 MG TABLET | $0.61814 | per EA | 23 Sep 2026 |
NADAC: average price US retail pharmacies pay to buy the medicine. NHS Drug Tariff Part VIIIA: basic price reimbursed to pharmacies in England and Wales.
Safety signals and safety-related labeling changes
- US FDA 6 Mar 2026 QSYMIA — safety-related labeling change
Labeling sections changed: Contraindications; Warnings and Precautions; Adverse Reactions; Drug Interactions; Use in Specific Populations; Patient Counseling Information / Patient Information / Medication Guide
Combinations containing Phentermine
Values as published by each source: SFDA human drug list (4-2026, as published by the Council of Health Insurance; indications from the CHI Daman Drug Formulary), Drugs@FDA, EMA medicines data, Health Canada Drug Product Database (Open Government Licence – Canada), CMS NADAC, NHS Drug Tariff Part VIIIA (NHSBSA Copyright, Open Government Licence v3.0), WHO Model List of Essential Medicines (CC BY 3.0 IGO; regrouped by active substance, not created by WHO), EMA PRAC, US FDA safety-related labeling changes and MHRA Drug Safety Update (Open Government Licence v3.0). Sources and reuse. Not a substitute for the official registers or the product information.